Crinetics Pharma - Approval Success for Palsonify Should Boost Results!

Business Driver: Crinetics Pharmaceuticals (CRNX) is focused on the discovery, development, and commercialization of new therapeutics for endocrine diseases and endocrine-related tumors. With Palsonify, it already has an FDA-approved medication. Palsonify is the first and only orally administered medication to be taken once daily for the treatment of acromegaly in adults who have not responded to surgery or for whom surgery is not an option. On January 5th, it announced a stock placement of 7.62 million shares at $45.95 per share. With the...